Male Cancer – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：371頁
文件格式：PDF
價 格：
USD 2,500 (Single-User License)
USD 5,000 (Multi-User License)
USD 7,500 (Global-User License)
USD 5,000 (Multi-User License)
USD 7,500 (Global-User License)
Male Cancer – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Male Cancer - Pipeline Review, H2 2012', provides an overview of the Male Cancer therapeutic pipeline. This report provides information on the therapeutic development for Male Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Male Cancer. 'Male Cancer - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Male Cancer.
- A review of the Male Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Male Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Male Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Male Cancer pipeline depth and focus of Male Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Male Cancer - Pipeline Review, H2 2012', provides an overview of the Male Cancer therapeutic pipeline. This report provides information on the therapeutic development for Male Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Male Cancer. 'Male Cancer - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Male Cancer.
- A review of the Male Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Male Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Male Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Male Cancer pipeline depth and focus of Male Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 15
Introduction 16
Global Markets Direct Report Coverage 16
Male Cancer Overview 17
Therapeutics Development 18
An Overview of Pipeline Products for Male Cancer 18
Male Cancer Therapeutics under Development by Companies 20
Male Cancer Therapeutics under Investigation by Universities/Institutes 36
Late Stage Products 47
Comparative Analysis 47
Mid Clinical Stage Products 48
Comparative Analysis 48
Early Clinical Stage Products 49
Comparative Analysis 49
Discovery and Pre-Clinical Stage Products 50
Comparative Analysis 50
Male Cancer Therapeutics – Products under Development by Companies 51
Male Cancer Therapeutics – Products under Investigation by Universities/Institutes 71
Companies Involved in Male Cancer Therapeutics Development 94
Bristol-Myers Squibb Company 94
Johnson & Johnson 95
Boehringer Ingelheim GmbH 96
Celsion Corporation 97
Abbott Laboratories 98
NsGene A/S 99
Amgen Inc. 100
Sanofi-Aventis 101
Adherex Technologies Inc. 102
AstraZeneca PLC 103
Eli Lilly and Company 104
Viralytics Ltd. 105
GlaxoSmithKline plc 106
Bioniche Life Sciences, Inc. 107
Genentech, Inc. 108
Inovio Biomedical Corporation 109
Bavarian Nordic A/S 110
Isis Pharmaceuticals, Inc. 111
Merck & Co., Inc. 112
AbGenomics International, Inc. 113
Oxford BioMedica plc 114
Generex Biotechnology Corporation 115
Takeda Pharmaceutical Company Limited 116
Plexxikon Inc. 117
Light Sciences Oncology, Inc. 118
Amorfix Life Sciences Ltd. 119
Ipsen S.A. 120
Panacea Pharmaceuticals, Inc. 121
Bio-Path Holdings, Inc. 122
BioSante Pharmaceuticals, Inc. 123
ZIOPHARM Oncology, Inc. 124
Millennium Pharmaceuticals, Inc. 125
Novartis AG 126
Aphios Corporation 127
Astellas Pharma Inc. 128
BioMarin Pharmaceutical Inc. 129
Cephalon, Inc. 130
Genta Incorporated 131
GTx, Inc. 132
Nippon Shinyaku Co., Ltd. 133
Orion Corporation 134
Pfizer Inc. 135
Teva Pharmaceutical Industries Limited 136
Cell Therapeutics, Inc. 137
Progenics Pharmaceuticals, Inc. 138
Santaris Pharma A/S 139
Exelixis, Inc. 140
Aduro BioTech 141
Menarini Group 142
Alfacell Corporation 143
Celgene Corporation 144
Bayer AG 145
MannKind Corporation 146
Merck KGaA 147
Advaxis, Inc. 148
Alchemia Limited 149
Addex Pharmaceuticals 150
Genesis Research and Development Corporation Ltd. 151
GW Pharmaceuticals plc 152
Hollis-Eden Pharmaceuticals, Inc. 153
Celldex Therapeutics, Inc. 154
Anavex Life Sciences Corp. 155
Cougar Biotechnology, Inc. 156
ValiRx Plc 157
Active Biotech AB 158
AEterna Zentaris Inc. 159
Antisense Therapeutics Limited 160
Lorus Therapeutics Inc 161
Bionomics Limited 162
Molecular Insight Pharmaceuticals, Inc. 163
Northwest Biotherapeutics, Inc. 164
Novelos Therapeutics, Inc. 165
Nymox Pharmaceutical Corporation 166
Cleveland BioLabs, Inc. 167
Oncolytics Biotech Inc. 168
Oncothyreon Inc 169
Compugen Ltd. 170
Osta Biotechnologies Inc. 171
Peregrine Pharmaceuticals, Inc. 172
Medivation, Inc. 173
La Jolla Pharmaceutical Company 174
Jazz Pharmaceuticals, Inc. 175
ADVENTRX Pharmaceuticals 176
Telik, Inc. 177
Soligenix, Inc. 178
Poniard Pharmaceuticals, Inc. 179
Regeneron Pharmaceuticals, Inc. 180
Champions Biotechnology, Inc. 181
Oncogenex Pharmaceuticals, Inc. 182
ProMetic Life Sciences Inc. 183
Progen Pharmaceuticals Limited 184
Green Cross Corporation 185
Innocell Corporation 186
Quest PharmaTech Inc. 187
Samaritan Pharmaceuticals, Inc. 188
Threshold Pharmaceuticals, Inc. 189
Synta Pharmaceuticals Corp. 190
Sareum Holdings plc 191
Oasmia Pharmaceutical AB 192
e-Therapeutics plc 193
RXi Pharmaceuticals Corporation 194
Hybrigenics S.A. 195
Rexahn Pharmaceuticals, Inc. 196
Merrion Pharmaceuticals Plc 197
Emiliem, Inc. 198
Oryzon 199
Angelini Group 200
Debiopharm Group 201
Antisense Pharma GmbH 202
Colby Pharmaceutical Company 203
Avanti Therapeutics 204
Camurus AB 205
Immupharma Plc 206
Phosphagenics Limited 207
Actis Biologics, Inc 208
Nerviano Medical Sciences S.r.l. 209
Med Discovery SA 210
Pro-Cure Therapeutics Limited 211
Vaxon Biotech 212
Advantagene, Inc. 213
CureVac GmbH 214
Alethia Biotherapeutics Inc. 215
GenSpera, Inc. 216
Ascenta Therapeutics, Inc. 217
Tokai Pharmaceuticals, Inc. 218
Coronado Biosciences, Inc. 219
MacroGenics, Inc. 220
Pervasis Therapeutics, Inc. 221
Antyra, Inc. 222
Pantarhei Bioscience BV 223
Azaya Therapeutics, Inc. 224
GP Pharm, S.A. 225
IC-MedTech, Inc. 226
Iconic Therapeutics, Inc. 227
ProNAi Therapeutics, Inc. 228
Angion Biomedica Corp. 229
Jennerex Biotherapeutics, Inc. 230
Oakwood Laboratories L.L.C. 231
Axelar AB 232
Endocyte, Inc. 233
Omnitura Therapeutics Inc. 234
AndroScience Corporation 235
Pharminox Limited 236
Thrasos, Inc. 237
Immutep S.A. 238
KangLaiTe USA 239
NovaLead Pharma Pvt. Ltd. 240
Esperance Pharmaceuticals, Inc. 241
Mirna Therapeutics, Inc. 242
Omeros Corporation 243
Transtech Pharma, Inc. 244
ImmunoVaccine Technologies Inc. 245
Peptron, Inc. 246
Globeimmune, Inc. 247
Etubics Corporation 248
TSD Japan, Inc. 249
PepTcell Limited 250
Drais Pharmaceuticals, Inc. 251
Cellceutix Corporation 252
PharmaMar, S.A. 253
TVAX Biomedical, LLC 254
Genetic Immunity, LLC 255
Quintessence Biosciences, Inc. 256
Bellicum Pharmaceuticals, Inc. 257
Aprea AB. 258
Kinex Pharmaceuticals, LLC 259
Adamis Pharmaceuticals Corporation 260
Tigris Pharmaceuticals, Inc. 261
Cylene Pharmaceuticals, Inc. 262
Lipopharma 263
Viventia Biotechnologies Inc. 264
IRX Therapeutics, Inc. 265
TRACON Pharmaceuticals, Inc. 266
EndoCeutics, Inc. 267
Ferring Pharmaceuticals, Inc. 268
Advanced Cancer Therapeutics 269
Viamet Pharmaceuticals, Inc. 270
Elara Pharmaceuticals GmbH 271
Cancer Therapeutics CRC Pty Ltd 272
Targa Therapeutics Corp. 273
Aragon Pharmaceuticals, Inc. 274
Vakzine Projekt Management GmbH 275
BHR Pharma, LLC. 276
iCeutica, Inc. 277
Ausio Pharmaceuticals, LLC 278
Errant Gene Therapeutics, LLC 279
Mebiopharm Co., Ltd. 280
Polaris Group 281
EyeGene, Inc. 282
DEKK-TEC, Inc. 283
Agennix AG 284
Celleron Therapeutics Ltd 285
ISA Pharmaceuticals B.V. 286
ImQuest Life Sciences 287
CytoVac A/S 288
Male Cancer – Therapeutics Assessment 289
Assessment by Monotherapy Products 289
Assessment by Combination Products 290
Assessment by Route of Administration 291
Assessment by Molecule Type 293
Drug Profiles 296
Enzalutamide - Drug Profile 296
Leuprolide 22.5 - Drug Profile 298
Leuprolide 7.5 - Drug Profile 300
degarelix acetate one month formulation - Drug Profile 301
Lutrate Depot - Drug Profile 302
CB7630 + Prednisone - Drug Profile 304
Male Cancer Therapeutics – Drug Profile Updates 306
Male Cancer Therapeutics – Discontinued Products 315
Male Cancer Therapeutics - Dormant Products 324
Male Cancer – Product Development Milestones 362
Featured News & Press Releases 362
Appendix 369
Methodology 369
Coverage 369
Secondary Research 369
Primary Research 369
Expert Panel Validation 369
Contact Us 370
Disclaimer 370
List of Tables
Number of Products Under Development for Male Cancer, H2 2012 19
Products under Development for Male Cancer – Comparative Analysis, H2 2012 20
Number of Products under Development by Companies, H2 2012 22
Number of Products under Development by Companies, H2 2012 (Contd..1) 23
Number of Products under Development by Companies, H2 2012 (Contd..2) 24
Number of Products under Development by Companies, H2 2012 (Contd..3) 25
Number of Products under Development by Companies, H2 2012 (Contd..4) 26
Number of Products under Development by Companies, H2 2012 (Contd..5) 27
Number of Products under Development by Companies, H2 2012 (Contd..6) 28
Number of Products under Development by Companies, H2 2012 (Contd..7) 29
Number of Products under Development by Companies, H2 2012 (Contd..8) 30
Number of Products under Development by Companies, H2 2012 (Contd..9) 31
Number of Products under Development by Companies, H2 2012 (Contd..10) 32
Number of Products under Development by Companies, H2 2012 (Contd..11) 33
Number of Products under Development by Companies, H2 2012 (Contd..12) 34
Number of Products under Development by Companies, H2 2012 (Contd..13) 35
Number of Products under Development by Companies, H2 2012 (Contd..14) 36
Number of Products under Investigation by Universities/Institutes, H2 2012 38
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 39
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 40
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 41
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 42
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 43
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 44
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 45
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 46
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 47
Comparative Analysis by Late Stage Development, H2 2012 48
Comparative Analysis by Mid Clinical Stage Development, H2 2012 49
Comparative Analysis by Early Clinical Stage Development, H2 2012 50
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 51
Products under Development by Companies, H2 2012 52
Products under Development by Companies, H2 2012 (Contd..1) 53
Products under Development by Companies, H2 2012 (Contd..2) 54
Products under Development by Companies, H2 2012 (Contd..3) 55
Products under Development by Companies, H2 2012 (Contd..4) 56
Products under Development by Companies, H2 2012 (Contd..5) 57
Products under Development by Companies, H2 2012 (Contd..6) 58
Products under Development by Companies, H2 2012 (Contd..7) 59
Products under Development by Companies, H2 2012 (Contd..8) 60
Products under Development by Companies, H2 2012 (Contd..9) 61
Products under Development by Companies, H2 2012 (Contd..10) 62
Products under Development by Companies, H2 2012 (Contd..11) 63
Products under Development by Companies, H2 2012 (Contd..12) 64
Products under Development by Companies, H2 2012 (Contd..13) 65
Products under Development by Companies, H2 2012 (Contd..14) 66
Products under Development by Companies, H2 2012 (Contd..15) 67
Products under Development by Companies, H2 2012 (Contd..16) 68
Products under Development by Companies, H2 2012 (Contd..17) 69
Products under Development by Companies, H2 2012 (Contd..18) 70
Products under Development by Companies, H2 2012 (Contd..19) 71
Products under Investigation by Universities/Institutes, H2 2012 72
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 73
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 74
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 75
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 76
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 77
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 78
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 79
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 80
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 81
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 82
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 83
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 84
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 85
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 86
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 87
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 88
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 89
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 90
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 91
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 92
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 93
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 94
Bristol-Myers Squibb Company, H2 2012 95
Johnson & Johnson, H2 2012 96
Boehringer Ingelheim GmbH, H2 2012 97
Celsion Corporation, H2 2012 98
Abbott Laboratories, H2 2012 99
NsGene A/S, H2 2012 100
Amgen Inc., H2 2012 101
Sanofi-Aventis, H2 2012 102
Adherex Technologies Inc., H2 2012 103
AstraZeneca PLC, H2 2012 104
Eli Lilly and Company, H2 2012 105
Viralytics Ltd., H2 2012 106
GlaxoSmithKline plc, H2 2012 107
Bioniche Life Sciences, Inc., H2 2012 108
Genentech, Inc., H2 2012 109
Inovio Biomedical Corporation, H2 2012 110
Bavarian Nordic A/S, H2 2012 111
Isis Pharmaceuticals, Inc., H2 2012 112
Merck & Co., Inc., H2 2012 113
AbGenomics International, Inc., H2 2012 114
Oxford BioMedica plc, H2 2012 115
Generex Biotechnology Corporation, H2 2012 116
Takeda Pharmaceutical Company Limited, H2 2012 117
Plexxikon Inc., H2 2012 118
Light Sciences Oncology, Inc., H2 2012 119
Amorfix Life Sciences Ltd., H2 2012 120
Ipsen S.A., H2 2012 121
Panacea Pharmaceuticals, Inc., H2 2012 122
Bio-Path Holdings, Inc., H2 2012 123
BioSante Pharmaceuticals, Inc., H2 2012 124
ZIOPHARM Oncology, Inc., H2 2012 125
Millennium Pharmaceuticals, Inc., H2 2012 126
Novartis AG, H2 2012 127
Aphios Corporation, H2 2012 128
Astellas Pharma Inc., H2 2012 129
BioMarin Pharmaceutical Inc., H2 2012 130
Cephalon, Inc., H2 2012 131
Genta Incorporated, H2 2012 132
GTx, Inc., H2 2012 133
Nippon Shinyaku Co., Ltd., H2 2012 134
Orion Corporation, H2 2012 135
Pfizer Inc., H2 2012 136
Teva Pharmaceutical Industries Limited, H2 2012 137
Cell Therapeutics, Inc., H2 2012 138
Progenics Pharmaceuticals, Inc., H2 2012 139
Santaris Pharma A/S, H2 2012 140
Exelixis, Inc., H2 2012 141
Aduro BioTech, H2 2012 142
Menarini Group, H2 2012 143
Alfacell Corporation, H2 2012 144
Celgene Corporation, H2 2012 145
Bayer AG, H2 2012 146
MannKind Corporation, H2 2012 147
Merck KGaA, H2 2012 148
Advaxis, Inc., H2 2012 149
Alchemia Limited, H2 2012 150
Addex Pharmaceuticals, H2 2012 151
Genesis Research and Development Corporation Ltd., H2 2012 152
GW Pharmaceuticals plc, H2 2012 153
Hollis-Eden Pharmaceuticals, Inc., H2 2012 154
Celldex Therapeutics, Inc., H2 2012 155
Anavex Life Sciences Corp., H2 2012 156
Cougar Biotechnology, Inc., H2 2012 157
ValiRx Plc, H2 2012 158
Active Biotech AB, H2 2012 159
AEterna Zentaris Inc., H2 2012 160
Antisense Therapeutics Limited, H2 2012 161
Lorus Therapeutics Inc, H2 2012 162
Bionomics Limited, H2 2012 163
Molecular Insight Pharmaceuticals, Inc., H2 2012 164
Northwest Biotherapeutics, Inc., H2 2012 165
Novelos Therapeutics, Inc., H2 2012 166
Nymox Pharmaceutical Corporation, H2 2012 167
Cleveland BioLabs, Inc., H2 2012 168
Oncolytics Biotech Inc., H2 2012 169
Oncothyreon Inc, H2 2012 170
Compugen Ltd., H2 2012 171
Osta Biotechnologies Inc., H2 2012 172
Peregrine Pharmaceuticals, Inc., H2 2012 173
Medivation, Inc., H2 2012 174
La Jolla Pharmaceutical Company, H2 2012 175
Jazz Pharmaceuticals, Inc., H2 2012 176
ADVENTRX Pharmaceuticals, H2 2012 177
Telik, Inc., H2 2012 178
Soligenix, Inc., H2 2012 179
Poniard Pharmaceuticals, Inc., H2 2012 180
Regeneron Pharmaceuticals, Inc., H2 2012 181
Champions Biotechnology, Inc., H2 2012 182
Oncogenex Pharmaceuticals, Inc., H2 2012 183
ProMetic Life Sciences Inc., H2 2012 184
Progen Pharmaceuticals Limited, H2 2012 185
Green Cross Corporation, H2 2012 186
Innocell Corporation, H2 2012 187
Quest PharmaTech Inc., H2 2012 188
Samaritan Pharmaceuticals, Inc., H2 2012 189
Threshold Pharmaceuticals, Inc., H2 2012 190
Synta Pharmaceuticals Corp., H2 2012 191
Sareum Holdings plc, H2 2012 192
Oasmia Pharmaceutical AB, H2 2012 193
e-Therapeutics plc, H2 2012 194
RXi Pharmaceuticals Corporation, H2 2012 195
Hybrigenics S.A., H2 2012 196
Rexahn Pharmaceuticals, Inc., H2 2012 197
Merrion Pharmaceuticals Plc, H2 2012 198
Emiliem, Inc., H2 2012 199
Oryzon, H2 2012 200
Angelini Group, H2 2012 201
Debiopharm Group, H2 2012 202
Antisense Pharma GmbH, H2 2012 203
Colby Pharmaceutical Company, H2 2012 204
Avanti Therapeutics, H2 2012 205
Camurus AB, H2 2012 206
Immupharma Plc, H2 2012 207
Phosphagenics Limited, H2 2012 208
Actis Biologics, Inc, H2 2012 209
Nerviano Medical Sciences S.r.l., H2 2012 210
Med Discovery SA, H2 2012 211
Pro-Cure Therapeutics Limited, H2 2012 212
Vaxon Biotech, H2 2012 213
Advantagene, Inc., H2 2012 214
CureVac GmbH, H2 2012 215
Alethia Biotherapeutics Inc., H2 2012 216
GenSpera, Inc., H2 2012 217
Ascenta Therapeutics, Inc., H2 2012 218
Tokai Pharmaceuticals, Inc., H2 2012 219
Coronado Biosciences, Inc., H2 2012 220
MacroGenics, Inc., H2 2012 221
Pervasis Therapeutics, Inc., H2 2012 222
Antyra, Inc., H2 2012 223
Pantarhei Bioscience BV, H2 2012 224
Azaya Therapeutics, Inc., H2 2012 225
GP Pharm, S.A., H2 2012 226
IC-MedTech, Inc., H2 2012 227
Iconic Therapeutics, Inc., H2 2012 228
ProNAi Therapeutics, Inc., H2 2012 229
Angion Biomedica Corp., H2 2012 230
Jennerex Biotherapeutics, Inc., H2 2012 231
Oakwood Laboratories L.L.C., H2 2012 232
Axelar AB, H2 2012 233
Endocyte, Inc., H2 2012 234
Omnitura Therapeutics Inc., H2 2012 235
AndroScience Corporation, H2 2012 236
Pharminox Limited, H2 2012 237
Thrasos, Inc., H2 2012 238
Immutep S.A., H2 2012 239
KangLaiTe USA, H2 2012 240
NovaLead Pharma Pvt. Ltd., H2 2012 241
Esperance Pharmaceuticals, Inc., H2 2012 242
Mirna Therapeutics, Inc., H2 2012 243
Omeros Corporation, H2 2012 244
Transtech Pharma, Inc., H2 2012 245
ImmunoVaccine Technologies Inc., H2 2012 246
Peptron, Inc., H2 2012 247
Globeimmune, Inc., H2 2012 248
Etubics Corporation, H2 2012 249
TSD Japan, Inc., H2 2012 250
PepTcell Limited, H2 2012 251
Drais Pharmaceuticals, Inc., H2 2012 252
Cellceutix Corporation, H2 2012 253
PharmaMar, S.A., H2 2012 254
TVAX Biomedical, LLC, H2 2012 255
Genetic Immunity, LLC, H2 2012 256
Quintessence Biosciences, Inc., H2 2012 257
Bellicum Pharmaceuticals, Inc., H2 2012 258
Aprea AB., H2 2012 259
Kinex Pharmaceuticals, LLC, H2 2012 260
Adamis Pharmaceuticals Corporation, H2 2012 261
Tigris Pharmaceuticals, Inc., H2 2012 262
Cylene Pharmaceuticals, Inc., H2 2012 263
Lipopharma, H2 2012 264
Viventia Biotechnologies Inc., H2 2012 265
IRX Therapeutics, Inc., H2 2012 266
TRACON Pharmaceuticals, Inc., H2 2012 267
EndoCeutics, Inc., H2 2012 268
Ferring Pharmaceuticals, Inc., H2 2012 269
Advanced Cancer Therapeutics, H2 2012 270
Viamet Pharmaceuticals, Inc., H2 2012 271
Elara Pharmaceuticals GmbH, H2 2012 272
Cancer Therapeutics CRC Pty Ltd, H2 2012 273
Targa Therapeutics Corp., H2 2012 274
Aragon Pharmaceuticals, Inc., H2 2012 275
Vakzine Projekt Management GmbH, H2 2012 276
BHR Pharma, LLC., H2 2012 277
iCeutica, Inc., H2 2012 278
Ausio Pharmaceuticals, LLC, H2 2012 279
Errant Gene Therapeutics, LLC, H2 2012 280
Mebiopharm Co., Ltd., H2 2012 281
Polaris Group, H2 2012 282
EyeGene, Inc., H2 2012 283
DEKK-TEC, Inc., H2 2012 284
Agennix AG, H2 2012 285
Celleron Therapeutics Ltd, H2 2012 286
ISA Pharmaceuticals B.V., H2 2012 287
ImQuest Life Sciences, H2 2012 288
CytoVac A/S, H2 2012 289
Assessment by Monotherapy Products, H2 2012 290
Assessment by Combination Products, H2 2012 291
Assessment by Stage and Route of Administration, H2 2012 293
Assessment by Stage and Molecule Type, H2 2012 296
Male Cancer Therapeutics – Drug Profile Updates 307
Male Cancer Therapeutics – Discontinued Products 316
Male Cancer Therapeutics – Discontinued Products (Contd..1) 317
Male Cancer Therapeutics – Discontinued Products (Contd..2) 318
Male Cancer Therapeutics – Discontinued Products (Contd..3) 319
Male Cancer Therapeutics – Discontinued Products (Contd..4) 320
Male Cancer Therapeutics – Discontinued Products (Contd..5) 321
Male Cancer Therapeutics – Discontinued Products (Contd..6) 322
Male Cancer Therapeutics – Discontinued Products (Contd..7) 323
Male Cancer Therapeutics – Discontinued Products (Contd..8) 324
Male Cancer Therapeutics – Dormant Products 325
Male Cancer Therapeutics – Dormant Products (Contd..1) 326
Male Cancer Therapeutics – Dormant Products (Contd..2) 327
Male Cancer Therapeutics – Dormant Products (Contd..3) 328
Male Cancer Therapeutics – Dormant Products (Contd..4) 329
Male Cancer Therapeutics – Dormant Products (Contd..5) 330
Male Cancer Therapeutics – Dormant Products (Contd..6) 331
Male Cancer Therapeutics – Dormant Products (Contd..7) 332
Male Cancer Therapeutics – Dormant Products (Contd..8) 333
Male Cancer Therapeutics – Dormant Products (Contd..9) 334
Male Cancer Therapeutics – Dormant Products (Contd..10) 335
Male Cancer Therapeutics – Dormant Products (Contd..11) 336
Male Cancer Therapeutics – Dormant Products (Contd..12) 337
Male Cancer Therapeutics – Dormant Products (Contd..13) 338
Male Cancer Therapeutics – Dormant Products (Contd..14) 339
Male Cancer Therapeutics – Dormant Products (Contd..15) 340
Male Cancer Therapeutics – Dormant Products (Contd..16) 341
Male Cancer Therapeutics – Dormant Products (Contd..17) 342
Male Cancer Therapeutics – Dormant Products (Contd..18) 343
Male Cancer Therapeutics – Dormant Products (Contd..19) 344
Male Cancer Therapeutics – Dormant Products (Contd..20) 345
Male Cancer Therapeutics – Dormant Products (Contd..21) 346
Male Cancer Therapeutics – Dormant Products (Contd..22) 347
Male Cancer Therapeutics – Dormant Products (Contd..23) 348
Male Cancer Therapeutics – Dormant Products (Contd..24) 349
Male Cancer Therapeutics – Dormant Products (Contd..25) 350
Male Cancer Therapeutics – Dormant Products (Contd..26) 351
Male Cancer Therapeutics – Dormant Products (Contd..27) 352
Male Cancer Therapeutics – Dormant Products (Contd..28) 353
Male Cancer Therapeutics – Dormant Products (Contd..29) 354
Male Cancer Therapeutics – Dormant Products (Contd..30) 355
Male Cancer Therapeutics – Dormant Products (Contd..31) 356
Male Cancer Therapeutics – Dormant Products (Contd..32) 357
Male Cancer Therapeutics – Dormant Products (Contd..33) 358
Male Cancer Therapeutics – Dormant Products (Contd..34) 359
Male Cancer Therapeutics – Dormant Products (Contd..35) 360
Male Cancer Therapeutics – Dormant Products (Contd..36) 361
Male Cancer Therapeutics – Dormant Products (Contd..37) 362
List of Figures
Number of Products under Development for Male Cancer, H2 2012 19
Products under Development for Male Cancer – Comparative Analysis, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 37
Late Stage Products, H2 2012 48
Mid Clinical Stage Products, H2 2012 49
Early Clinical Stage Products, H2 2012 50
Discovery and Pre-Clinical Stage Products, H2 2012 51
Assessment by Monotherapy Products, H2 2012 290
Assessment by Combination Products, H2 2012 291
Assessment by Route of Administration, H2 2012 292
Assessment by Stage and Route of Administration, H2 2012 293
Assessment by Molecule Type, H2 2012 294
Assessment by Stage and Molecule Type, H2 2012 295
Table of Contents 2
List of Tables 7
List of Figures 15
Introduction 16
Global Markets Direct Report Coverage 16
Male Cancer Overview 17
Therapeutics Development 18
An Overview of Pipeline Products for Male Cancer 18
Male Cancer Therapeutics under Development by Companies 20
Male Cancer Therapeutics under Investigation by Universities/Institutes 36
Late Stage Products 47
Comparative Analysis 47
Mid Clinical Stage Products 48
Comparative Analysis 48
Early Clinical Stage Products 49
Comparative Analysis 49
Discovery and Pre-Clinical Stage Products 50
Comparative Analysis 50
Male Cancer Therapeutics – Products under Development by Companies 51
Male Cancer Therapeutics – Products under Investigation by Universities/Institutes 71
Companies Involved in Male Cancer Therapeutics Development 94
Bristol-Myers Squibb Company 94
Johnson & Johnson 95
Boehringer Ingelheim GmbH 96
Celsion Corporation 97
Abbott Laboratories 98
NsGene A/S 99
Amgen Inc. 100
Sanofi-Aventis 101
Adherex Technologies Inc. 102
AstraZeneca PLC 103
Eli Lilly and Company 104
Viralytics Ltd. 105
GlaxoSmithKline plc 106
Bioniche Life Sciences, Inc. 107
Genentech, Inc. 108
Inovio Biomedical Corporation 109
Bavarian Nordic A/S 110
Isis Pharmaceuticals, Inc. 111
Merck & Co., Inc. 112
AbGenomics International, Inc. 113
Oxford BioMedica plc 114
Generex Biotechnology Corporation 115
Takeda Pharmaceutical Company Limited 116
Plexxikon Inc. 117
Light Sciences Oncology, Inc. 118
Amorfix Life Sciences Ltd. 119
Ipsen S.A. 120
Panacea Pharmaceuticals, Inc. 121
Bio-Path Holdings, Inc. 122
BioSante Pharmaceuticals, Inc. 123
ZIOPHARM Oncology, Inc. 124
Millennium Pharmaceuticals, Inc. 125
Novartis AG 126
Aphios Corporation 127
Astellas Pharma Inc. 128
BioMarin Pharmaceutical Inc. 129
Cephalon, Inc. 130
Genta Incorporated 131
GTx, Inc. 132
Nippon Shinyaku Co., Ltd. 133
Orion Corporation 134
Pfizer Inc. 135
Teva Pharmaceutical Industries Limited 136
Cell Therapeutics, Inc. 137
Progenics Pharmaceuticals, Inc. 138
Santaris Pharma A/S 139
Exelixis, Inc. 140
Aduro BioTech 141
Menarini Group 142
Alfacell Corporation 143
Celgene Corporation 144
Bayer AG 145
MannKind Corporation 146
Merck KGaA 147
Advaxis, Inc. 148
Alchemia Limited 149
Addex Pharmaceuticals 150
Genesis Research and Development Corporation Ltd. 151
GW Pharmaceuticals plc 152
Hollis-Eden Pharmaceuticals, Inc. 153
Celldex Therapeutics, Inc. 154
Anavex Life Sciences Corp. 155
Cougar Biotechnology, Inc. 156
ValiRx Plc 157
Active Biotech AB 158
AEterna Zentaris Inc. 159
Antisense Therapeutics Limited 160
Lorus Therapeutics Inc 161
Bionomics Limited 162
Molecular Insight Pharmaceuticals, Inc. 163
Northwest Biotherapeutics, Inc. 164
Novelos Therapeutics, Inc. 165
Nymox Pharmaceutical Corporation 166
Cleveland BioLabs, Inc. 167
Oncolytics Biotech Inc. 168
Oncothyreon Inc 169
Compugen Ltd. 170
Osta Biotechnologies Inc. 171
Peregrine Pharmaceuticals, Inc. 172
Medivation, Inc. 173
La Jolla Pharmaceutical Company 174
Jazz Pharmaceuticals, Inc. 175
ADVENTRX Pharmaceuticals 176
Telik, Inc. 177
Soligenix, Inc. 178
Poniard Pharmaceuticals, Inc. 179
Regeneron Pharmaceuticals, Inc. 180
Champions Biotechnology, Inc. 181
Oncogenex Pharmaceuticals, Inc. 182
ProMetic Life Sciences Inc. 183
Progen Pharmaceuticals Limited 184
Green Cross Corporation 185
Innocell Corporation 186
Quest PharmaTech Inc. 187
Samaritan Pharmaceuticals, Inc. 188
Threshold Pharmaceuticals, Inc. 189
Synta Pharmaceuticals Corp. 190
Sareum Holdings plc 191
Oasmia Pharmaceutical AB 192
e-Therapeutics plc 193
RXi Pharmaceuticals Corporation 194
Hybrigenics S.A. 195
Rexahn Pharmaceuticals, Inc. 196
Merrion Pharmaceuticals Plc 197
Emiliem, Inc. 198
Oryzon 199
Angelini Group 200
Debiopharm Group 201
Antisense Pharma GmbH 202
Colby Pharmaceutical Company 203
Avanti Therapeutics 204
Camurus AB 205
Immupharma Plc 206
Phosphagenics Limited 207
Actis Biologics, Inc 208
Nerviano Medical Sciences S.r.l. 209
Med Discovery SA 210
Pro-Cure Therapeutics Limited 211
Vaxon Biotech 212
Advantagene, Inc. 213
CureVac GmbH 214
Alethia Biotherapeutics Inc. 215
GenSpera, Inc. 216
Ascenta Therapeutics, Inc. 217
Tokai Pharmaceuticals, Inc. 218
Coronado Biosciences, Inc. 219
MacroGenics, Inc. 220
Pervasis Therapeutics, Inc. 221
Antyra, Inc. 222
Pantarhei Bioscience BV 223
Azaya Therapeutics, Inc. 224
GP Pharm, S.A. 225
IC-MedTech, Inc. 226
Iconic Therapeutics, Inc. 227
ProNAi Therapeutics, Inc. 228
Angion Biomedica Corp. 229
Jennerex Biotherapeutics, Inc. 230
Oakwood Laboratories L.L.C. 231
Axelar AB 232
Endocyte, Inc. 233
Omnitura Therapeutics Inc. 234
AndroScience Corporation 235
Pharminox Limited 236
Thrasos, Inc. 237
Immutep S.A. 238
KangLaiTe USA 239
NovaLead Pharma Pvt. Ltd. 240
Esperance Pharmaceuticals, Inc. 241
Mirna Therapeutics, Inc. 242
Omeros Corporation 243
Transtech Pharma, Inc. 244
ImmunoVaccine Technologies Inc. 245
Peptron, Inc. 246
Globeimmune, Inc. 247
Etubics Corporation 248
TSD Japan, Inc. 249
PepTcell Limited 250
Drais Pharmaceuticals, Inc. 251
Cellceutix Corporation 252
PharmaMar, S.A. 253
TVAX Biomedical, LLC 254
Genetic Immunity, LLC 255
Quintessence Biosciences, Inc. 256
Bellicum Pharmaceuticals, Inc. 257
Aprea AB. 258
Kinex Pharmaceuticals, LLC 259
Adamis Pharmaceuticals Corporation 260
Tigris Pharmaceuticals, Inc. 261
Cylene Pharmaceuticals, Inc. 262
Lipopharma 263
Viventia Biotechnologies Inc. 264
IRX Therapeutics, Inc. 265
TRACON Pharmaceuticals, Inc. 266
EndoCeutics, Inc. 267
Ferring Pharmaceuticals, Inc. 268
Advanced Cancer Therapeutics 269
Viamet Pharmaceuticals, Inc. 270
Elara Pharmaceuticals GmbH 271
Cancer Therapeutics CRC Pty Ltd 272
Targa Therapeutics Corp. 273
Aragon Pharmaceuticals, Inc. 274
Vakzine Projekt Management GmbH 275
BHR Pharma, LLC. 276
iCeutica, Inc. 277
Ausio Pharmaceuticals, LLC 278
Errant Gene Therapeutics, LLC 279
Mebiopharm Co., Ltd. 280
Polaris Group 281
EyeGene, Inc. 282
DEKK-TEC, Inc. 283
Agennix AG 284
Celleron Therapeutics Ltd 285
ISA Pharmaceuticals B.V. 286
ImQuest Life Sciences 287
CytoVac A/S 288
Male Cancer – Therapeutics Assessment 289
Assessment by Monotherapy Products 289
Assessment by Combination Products 290
Assessment by Route of Administration 291
Assessment by Molecule Type 293
Drug Profiles 296
Enzalutamide - Drug Profile 296
Leuprolide 22.5 - Drug Profile 298
Leuprolide 7.5 - Drug Profile 300
degarelix acetate one month formulation - Drug Profile 301
Lutrate Depot - Drug Profile 302
CB7630 + Prednisone - Drug Profile 304
Male Cancer Therapeutics – Drug Profile Updates 306
Male Cancer Therapeutics – Discontinued Products 315
Male Cancer Therapeutics - Dormant Products 324
Male Cancer – Product Development Milestones 362
Featured News & Press Releases 362
Appendix 369
Methodology 369
Coverage 369
Secondary Research 369
Primary Research 369
Expert Panel Validation 369
Contact Us 370
Disclaimer 370
List of Tables
Number of Products Under Development for Male Cancer, H2 2012 19
Products under Development for Male Cancer – Comparative Analysis, H2 2012 20
Number of Products under Development by Companies, H2 2012 22
Number of Products under Development by Companies, H2 2012 (Contd..1) 23
Number of Products under Development by Companies, H2 2012 (Contd..2) 24
Number of Products under Development by Companies, H2 2012 (Contd..3) 25
Number of Products under Development by Companies, H2 2012 (Contd..4) 26
Number of Products under Development by Companies, H2 2012 (Contd..5) 27
Number of Products under Development by Companies, H2 2012 (Contd..6) 28
Number of Products under Development by Companies, H2 2012 (Contd..7) 29
Number of Products under Development by Companies, H2 2012 (Contd..8) 30
Number of Products under Development by Companies, H2 2012 (Contd..9) 31
Number of Products under Development by Companies, H2 2012 (Contd..10) 32
Number of Products under Development by Companies, H2 2012 (Contd..11) 33
Number of Products under Development by Companies, H2 2012 (Contd..12) 34
Number of Products under Development by Companies, H2 2012 (Contd..13) 35
Number of Products under Development by Companies, H2 2012 (Contd..14) 36
Number of Products under Investigation by Universities/Institutes, H2 2012 38
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 39
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 40
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 41
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 42
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 43
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 44
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 45
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 46
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 47
Comparative Analysis by Late Stage Development, H2 2012 48
Comparative Analysis by Mid Clinical Stage Development, H2 2012 49
Comparative Analysis by Early Clinical Stage Development, H2 2012 50
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 51
Products under Development by Companies, H2 2012 52
Products under Development by Companies, H2 2012 (Contd..1) 53
Products under Development by Companies, H2 2012 (Contd..2) 54
Products under Development by Companies, H2 2012 (Contd..3) 55
Products under Development by Companies, H2 2012 (Contd..4) 56
Products under Development by Companies, H2 2012 (Contd..5) 57
Products under Development by Companies, H2 2012 (Contd..6) 58
Products under Development by Companies, H2 2012 (Contd..7) 59
Products under Development by Companies, H2 2012 (Contd..8) 60
Products under Development by Companies, H2 2012 (Contd..9) 61
Products under Development by Companies, H2 2012 (Contd..10) 62
Products under Development by Companies, H2 2012 (Contd..11) 63
Products under Development by Companies, H2 2012 (Contd..12) 64
Products under Development by Companies, H2 2012 (Contd..13) 65
Products under Development by Companies, H2 2012 (Contd..14) 66
Products under Development by Companies, H2 2012 (Contd..15) 67
Products under Development by Companies, H2 2012 (Contd..16) 68
Products under Development by Companies, H2 2012 (Contd..17) 69
Products under Development by Companies, H2 2012 (Contd..18) 70
Products under Development by Companies, H2 2012 (Contd..19) 71
Products under Investigation by Universities/Institutes, H2 2012 72
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 73
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 74
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 75
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 76
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 77
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 78
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 79
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 80
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 81
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 82
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 83
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 84
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 85
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 86
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 87
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 88
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 89
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 90
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 91
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 92
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 93
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 94
Bristol-Myers Squibb Company, H2 2012 95
Johnson & Johnson, H2 2012 96
Boehringer Ingelheim GmbH, H2 2012 97
Celsion Corporation, H2 2012 98
Abbott Laboratories, H2 2012 99
NsGene A/S, H2 2012 100
Amgen Inc., H2 2012 101
Sanofi-Aventis, H2 2012 102
Adherex Technologies Inc., H2 2012 103
AstraZeneca PLC, H2 2012 104
Eli Lilly and Company, H2 2012 105
Viralytics Ltd., H2 2012 106
GlaxoSmithKline plc, H2 2012 107
Bioniche Life Sciences, Inc., H2 2012 108
Genentech, Inc., H2 2012 109
Inovio Biomedical Corporation, H2 2012 110
Bavarian Nordic A/S, H2 2012 111
Isis Pharmaceuticals, Inc., H2 2012 112
Merck & Co., Inc., H2 2012 113
AbGenomics International, Inc., H2 2012 114
Oxford BioMedica plc, H2 2012 115
Generex Biotechnology Corporation, H2 2012 116
Takeda Pharmaceutical Company Limited, H2 2012 117
Plexxikon Inc., H2 2012 118
Light Sciences Oncology, Inc., H2 2012 119
Amorfix Life Sciences Ltd., H2 2012 120
Ipsen S.A., H2 2012 121
Panacea Pharmaceuticals, Inc., H2 2012 122
Bio-Path Holdings, Inc., H2 2012 123
BioSante Pharmaceuticals, Inc., H2 2012 124
ZIOPHARM Oncology, Inc., H2 2012 125
Millennium Pharmaceuticals, Inc., H2 2012 126
Novartis AG, H2 2012 127
Aphios Corporation, H2 2012 128
Astellas Pharma Inc., H2 2012 129
BioMarin Pharmaceutical Inc., H2 2012 130
Cephalon, Inc., H2 2012 131
Genta Incorporated, H2 2012 132
GTx, Inc., H2 2012 133
Nippon Shinyaku Co., Ltd., H2 2012 134
Orion Corporation, H2 2012 135
Pfizer Inc., H2 2012 136
Teva Pharmaceutical Industries Limited, H2 2012 137
Cell Therapeutics, Inc., H2 2012 138
Progenics Pharmaceuticals, Inc., H2 2012 139
Santaris Pharma A/S, H2 2012 140
Exelixis, Inc., H2 2012 141
Aduro BioTech, H2 2012 142
Menarini Group, H2 2012 143
Alfacell Corporation, H2 2012 144
Celgene Corporation, H2 2012 145
Bayer AG, H2 2012 146
MannKind Corporation, H2 2012 147
Merck KGaA, H2 2012 148
Advaxis, Inc., H2 2012 149
Alchemia Limited, H2 2012 150
Addex Pharmaceuticals, H2 2012 151
Genesis Research and Development Corporation Ltd., H2 2012 152
GW Pharmaceuticals plc, H2 2012 153
Hollis-Eden Pharmaceuticals, Inc., H2 2012 154
Celldex Therapeutics, Inc., H2 2012 155
Anavex Life Sciences Corp., H2 2012 156
Cougar Biotechnology, Inc., H2 2012 157
ValiRx Plc, H2 2012 158
Active Biotech AB, H2 2012 159
AEterna Zentaris Inc., H2 2012 160
Antisense Therapeutics Limited, H2 2012 161
Lorus Therapeutics Inc, H2 2012 162
Bionomics Limited, H2 2012 163
Molecular Insight Pharmaceuticals, Inc., H2 2012 164
Northwest Biotherapeutics, Inc., H2 2012 165
Novelos Therapeutics, Inc., H2 2012 166
Nymox Pharmaceutical Corporation, H2 2012 167
Cleveland BioLabs, Inc., H2 2012 168
Oncolytics Biotech Inc., H2 2012 169
Oncothyreon Inc, H2 2012 170
Compugen Ltd., H2 2012 171
Osta Biotechnologies Inc., H2 2012 172
Peregrine Pharmaceuticals, Inc., H2 2012 173
Medivation, Inc., H2 2012 174
La Jolla Pharmaceutical Company, H2 2012 175
Jazz Pharmaceuticals, Inc., H2 2012 176
ADVENTRX Pharmaceuticals, H2 2012 177
Telik, Inc., H2 2012 178
Soligenix, Inc., H2 2012 179
Poniard Pharmaceuticals, Inc., H2 2012 180
Regeneron Pharmaceuticals, Inc., H2 2012 181
Champions Biotechnology, Inc., H2 2012 182
Oncogenex Pharmaceuticals, Inc., H2 2012 183
ProMetic Life Sciences Inc., H2 2012 184
Progen Pharmaceuticals Limited, H2 2012 185
Green Cross Corporation, H2 2012 186
Innocell Corporation, H2 2012 187
Quest PharmaTech Inc., H2 2012 188
Samaritan Pharmaceuticals, Inc., H2 2012 189
Threshold Pharmaceuticals, Inc., H2 2012 190
Synta Pharmaceuticals Corp., H2 2012 191
Sareum Holdings plc, H2 2012 192
Oasmia Pharmaceutical AB, H2 2012 193
e-Therapeutics plc, H2 2012 194
RXi Pharmaceuticals Corporation, H2 2012 195
Hybrigenics S.A., H2 2012 196
Rexahn Pharmaceuticals, Inc., H2 2012 197
Merrion Pharmaceuticals Plc, H2 2012 198
Emiliem, Inc., H2 2012 199
Oryzon, H2 2012 200
Angelini Group, H2 2012 201
Debiopharm Group, H2 2012 202
Antisense Pharma GmbH, H2 2012 203
Colby Pharmaceutical Company, H2 2012 204
Avanti Therapeutics, H2 2012 205
Camurus AB, H2 2012 206
Immupharma Plc, H2 2012 207
Phosphagenics Limited, H2 2012 208
Actis Biologics, Inc, H2 2012 209
Nerviano Medical Sciences S.r.l., H2 2012 210
Med Discovery SA, H2 2012 211
Pro-Cure Therapeutics Limited, H2 2012 212
Vaxon Biotech, H2 2012 213
Advantagene, Inc., H2 2012 214
CureVac GmbH, H2 2012 215
Alethia Biotherapeutics Inc., H2 2012 216
GenSpera, Inc., H2 2012 217
Ascenta Therapeutics, Inc., H2 2012 218
Tokai Pharmaceuticals, Inc., H2 2012 219
Coronado Biosciences, Inc., H2 2012 220
MacroGenics, Inc., H2 2012 221
Pervasis Therapeutics, Inc., H2 2012 222
Antyra, Inc., H2 2012 223
Pantarhei Bioscience BV, H2 2012 224
Azaya Therapeutics, Inc., H2 2012 225
GP Pharm, S.A., H2 2012 226
IC-MedTech, Inc., H2 2012 227
Iconic Therapeutics, Inc., H2 2012 228
ProNAi Therapeutics, Inc., H2 2012 229
Angion Biomedica Corp., H2 2012 230
Jennerex Biotherapeutics, Inc., H2 2012 231
Oakwood Laboratories L.L.C., H2 2012 232
Axelar AB, H2 2012 233
Endocyte, Inc., H2 2012 234
Omnitura Therapeutics Inc., H2 2012 235
AndroScience Corporation, H2 2012 236
Pharminox Limited, H2 2012 237
Thrasos, Inc., H2 2012 238
Immutep S.A., H2 2012 239
KangLaiTe USA, H2 2012 240
NovaLead Pharma Pvt. Ltd., H2 2012 241
Esperance Pharmaceuticals, Inc., H2 2012 242
Mirna Therapeutics, Inc., H2 2012 243
Omeros Corporation, H2 2012 244
Transtech Pharma, Inc., H2 2012 245
ImmunoVaccine Technologies Inc., H2 2012 246
Peptron, Inc., H2 2012 247
Globeimmune, Inc., H2 2012 248
Etubics Corporation, H2 2012 249
TSD Japan, Inc., H2 2012 250
PepTcell Limited, H2 2012 251
Drais Pharmaceuticals, Inc., H2 2012 252
Cellceutix Corporation, H2 2012 253
PharmaMar, S.A., H2 2012 254
TVAX Biomedical, LLC, H2 2012 255
Genetic Immunity, LLC, H2 2012 256
Quintessence Biosciences, Inc., H2 2012 257
Bellicum Pharmaceuticals, Inc., H2 2012 258
Aprea AB., H2 2012 259
Kinex Pharmaceuticals, LLC, H2 2012 260
Adamis Pharmaceuticals Corporation, H2 2012 261
Tigris Pharmaceuticals, Inc., H2 2012 262
Cylene Pharmaceuticals, Inc., H2 2012 263
Lipopharma, H2 2012 264
Viventia Biotechnologies Inc., H2 2012 265
IRX Therapeutics, Inc., H2 2012 266
TRACON Pharmaceuticals, Inc., H2 2012 267
EndoCeutics, Inc., H2 2012 268
Ferring Pharmaceuticals, Inc., H2 2012 269
Advanced Cancer Therapeutics, H2 2012 270
Viamet Pharmaceuticals, Inc., H2 2012 271
Elara Pharmaceuticals GmbH, H2 2012 272
Cancer Therapeutics CRC Pty Ltd, H2 2012 273
Targa Therapeutics Corp., H2 2012 274
Aragon Pharmaceuticals, Inc., H2 2012 275
Vakzine Projekt Management GmbH, H2 2012 276
BHR Pharma, LLC., H2 2012 277
iCeutica, Inc., H2 2012 278
Ausio Pharmaceuticals, LLC, H2 2012 279
Errant Gene Therapeutics, LLC, H2 2012 280
Mebiopharm Co., Ltd., H2 2012 281
Polaris Group, H2 2012 282
EyeGene, Inc., H2 2012 283
DEKK-TEC, Inc., H2 2012 284
Agennix AG, H2 2012 285
Celleron Therapeutics Ltd, H2 2012 286
ISA Pharmaceuticals B.V., H2 2012 287
ImQuest Life Sciences, H2 2012 288
CytoVac A/S, H2 2012 289
Assessment by Monotherapy Products, H2 2012 290
Assessment by Combination Products, H2 2012 291
Assessment by Stage and Route of Administration, H2 2012 293
Assessment by Stage and Molecule Type, H2 2012 296
Male Cancer Therapeutics – Drug Profile Updates 307
Male Cancer Therapeutics – Discontinued Products 316
Male Cancer Therapeutics – Discontinued Products (Contd..1) 317
Male Cancer Therapeutics – Discontinued Products (Contd..2) 318
Male Cancer Therapeutics – Discontinued Products (Contd..3) 319
Male Cancer Therapeutics – Discontinued Products (Contd..4) 320
Male Cancer Therapeutics – Discontinued Products (Contd..5) 321
Male Cancer Therapeutics – Discontinued Products (Contd..6) 322
Male Cancer Therapeutics – Discontinued Products (Contd..7) 323
Male Cancer Therapeutics – Discontinued Products (Contd..8) 324
Male Cancer Therapeutics – Dormant Products 325
Male Cancer Therapeutics – Dormant Products (Contd..1) 326
Male Cancer Therapeutics – Dormant Products (Contd..2) 327
Male Cancer Therapeutics – Dormant Products (Contd..3) 328
Male Cancer Therapeutics – Dormant Products (Contd..4) 329
Male Cancer Therapeutics – Dormant Products (Contd..5) 330
Male Cancer Therapeutics – Dormant Products (Contd..6) 331
Male Cancer Therapeutics – Dormant Products (Contd..7) 332
Male Cancer Therapeutics – Dormant Products (Contd..8) 333
Male Cancer Therapeutics – Dormant Products (Contd..9) 334
Male Cancer Therapeutics – Dormant Products (Contd..10) 335
Male Cancer Therapeutics – Dormant Products (Contd..11) 336
Male Cancer Therapeutics – Dormant Products (Contd..12) 337
Male Cancer Therapeutics – Dormant Products (Contd..13) 338
Male Cancer Therapeutics – Dormant Products (Contd..14) 339
Male Cancer Therapeutics – Dormant Products (Contd..15) 340
Male Cancer Therapeutics – Dormant Products (Contd..16) 341
Male Cancer Therapeutics – Dormant Products (Contd..17) 342
Male Cancer Therapeutics – Dormant Products (Contd..18) 343
Male Cancer Therapeutics – Dormant Products (Contd..19) 344
Male Cancer Therapeutics – Dormant Products (Contd..20) 345
Male Cancer Therapeutics – Dormant Products (Contd..21) 346
Male Cancer Therapeutics – Dormant Products (Contd..22) 347
Male Cancer Therapeutics – Dormant Products (Contd..23) 348
Male Cancer Therapeutics – Dormant Products (Contd..24) 349
Male Cancer Therapeutics – Dormant Products (Contd..25) 350
Male Cancer Therapeutics – Dormant Products (Contd..26) 351
Male Cancer Therapeutics – Dormant Products (Contd..27) 352
Male Cancer Therapeutics – Dormant Products (Contd..28) 353
Male Cancer Therapeutics – Dormant Products (Contd..29) 354
Male Cancer Therapeutics – Dormant Products (Contd..30) 355
Male Cancer Therapeutics – Dormant Products (Contd..31) 356
Male Cancer Therapeutics – Dormant Products (Contd..32) 357
Male Cancer Therapeutics – Dormant Products (Contd..33) 358
Male Cancer Therapeutics – Dormant Products (Contd..34) 359
Male Cancer Therapeutics – Dormant Products (Contd..35) 360
Male Cancer Therapeutics – Dormant Products (Contd..36) 361
Male Cancer Therapeutics – Dormant Products (Contd..37) 362
List of Figures
Number of Products under Development for Male Cancer, H2 2012 19
Products under Development for Male Cancer – Comparative Analysis, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 37
Late Stage Products, H2 2012 48
Mid Clinical Stage Products, H2 2012 49
Early Clinical Stage Products, H2 2012 50
Discovery and Pre-Clinical Stage Products, H2 2012 51
Assessment by Monotherapy Products, H2 2012 290
Assessment by Combination Products, H2 2012 291
Assessment by Route of Administration, H2 2012 292
Assessment by Stage and Route of Administration, H2 2012 293
Assessment by Molecule Type, H2 2012 294
Assessment by Stage and Molecule Type, H2 2012 295
